AU2018324427B2 - Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics - Google Patents

Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics Download PDF

Info

Publication number
AU2018324427B2
AU2018324427B2 AU2018324427A AU2018324427A AU2018324427B2 AU 2018324427 B2 AU2018324427 B2 AU 2018324427B2 AU 2018324427 A AU2018324427 A AU 2018324427A AU 2018324427 A AU2018324427 A AU 2018324427A AU 2018324427 B2 AU2018324427 B2 AU 2018324427B2
Authority
AU
Australia
Prior art keywords
arginine
tranexamic acid
virus
viral
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018324427A
Other languages
English (en)
Other versions
AU2018324427A1 (en
Inventor
Frank Murdock
Ronnea MURDOCK
W. Paul Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anti Viral Technologies LLC
Original Assignee
Anti Viral Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anti Viral Technologies LLC filed Critical Anti Viral Technologies LLC
Publication of AU2018324427A1 publication Critical patent/AU2018324427A1/en
Application granted granted Critical
Publication of AU2018324427B2 publication Critical patent/AU2018324427B2/en
Priority to AU2024203839A priority Critical patent/AU2024203839A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018324427A 2017-08-27 2018-08-09 Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics Active AU2018324427B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203839A AU2024203839A1 (en) 2017-08-27 2024-06-06 Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762550656P 2017-08-27 2017-08-27
US62/550,656 2017-08-27
US201862664555P 2018-04-30 2018-04-30
US62/664,555 2018-04-30
PCT/US2018/046023 WO2019045989A1 (en) 2017-08-27 2018-08-09 METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF LYSINE SYNTHETIC ANALOGUES AND MIMETICS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203839A Division AU2024203839A1 (en) 2017-08-27 2024-06-06 Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics

Publications (2)

Publication Number Publication Date
AU2018324427A1 AU2018324427A1 (en) 2020-04-09
AU2018324427B2 true AU2018324427B2 (en) 2024-03-07

Family

ID=65525881

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018324427A Active AU2018324427B2 (en) 2017-08-27 2018-08-09 Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
AU2024203839A Pending AU2024203839A1 (en) 2017-08-27 2024-06-06 Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203839A Pending AU2024203839A1 (en) 2017-08-27 2024-06-06 Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics

Country Status (11)

Country Link
US (2) US11413279B2 (enExample)
EP (1) EP3672584A4 (enExample)
JP (3) JP2020531586A (enExample)
KR (1) KR102706114B1 (enExample)
CN (1) CN111315374A (enExample)
AU (2) AU2018324427B2 (enExample)
BR (1) BR112020003735A2 (enExample)
CA (1) CA3073685A1 (enExample)
MX (2) MX2020002156A (enExample)
WO (1) WO2019045989A1 (enExample)
ZA (1) ZA202001472B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3156617A1 (en) * 2019-10-29 2021-05-06 W. Paul Stewart Synergistic combinations of synthetic lysine analogs, derivatives, mimetics, or prodrugs and pharmaceutical agents for enhanced efficacy
WO2021162879A1 (en) * 2020-02-14 2021-08-19 Tranexamic Technologies, Llc Methods and compositions for antimicrobial use of synthetic lysine analogs, derivatives, mimetics, and prodrugs
JP2022132181A (ja) * 2021-02-26 2022-09-07 ライオン株式会社 コロナウイルスの細胞侵入抑制剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120082677A1 (en) * 2010-10-01 2012-04-05 Sherif Salah Abdul Aziz Compositions for the treatment of hcv and hbv

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0789764B1 (en) * 1994-10-28 2002-01-09 Vitaleech Bioscience N.V. A novel family of protease inhibitors, and other biologic active substances
WO2000037071A1 (en) * 1998-12-21 2000-06-29 Aps Kbus 8 Nr. 4788 Topical treatment of skin disease
ES2156731B1 (es) * 1999-05-31 2002-02-16 Grifols Grupo Sa Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
US7056947B2 (en) 2002-07-05 2006-06-06 Georgia Tech Research Corp. Aza-peptide epoxides
JP4600882B2 (ja) * 2002-10-11 2010-12-22 第一三共株式会社 抗インフルエンザウイルス剤
JP2008115168A (ja) * 2006-10-12 2008-05-22 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤
JP5730211B2 (ja) * 2008-11-20 2015-06-03 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． ウイルスのアルギニン不活化
JP2010189301A (ja) * 2009-02-17 2010-09-02 Toshihito Eto 新型インフルエンザ感染症に対する医薬組成物およびその利用
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
CN103405384B (zh) * 2013-09-01 2015-05-13 吴静 氨甲环酸的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120082677A1 (en) * 2010-10-01 2012-04-05 Sherif Salah Abdul Aziz Compositions for the treatment of hcv and hbv

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOZITSKY V ET AL: "Anti-influenza Efficacy of Combination Apply of Proteolytic Inhibitor E-aminocaproic Acid with Neuraminidase Inhibitor Tamiflu", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 82, no. 2, 1 May 2009 (2009-05-01), pages A34 *
OLLIER LAURENCE ET AL: "High permissivity of human HepG2 hepatoma cells for influenza viruses.", JOURNAL OF CLINICAL MICROBIOLOGY DEC 2004, vol. 42, no. 12, December 2004 (2004-12-01), pages 5861 - 5865, X *

Also Published As

Publication number Publication date
MX2023009499A (es) 2023-08-23
CN111315374A (zh) 2020-06-19
KR102706114B1 (ko) 2024-09-11
JP2023123440A (ja) 2023-09-05
WO2019045989A1 (en) 2019-03-07
US11413279B2 (en) 2022-08-16
BR112020003735A2 (pt) 2020-09-01
AU2018324427A1 (en) 2020-04-09
KR20200052310A (ko) 2020-05-14
CA3073685A1 (en) 2019-03-07
EP3672584A4 (en) 2021-05-05
ZA202001472B (en) 2022-05-25
MX2020002156A (es) 2020-07-20
JP2020531586A (ja) 2020-11-05
EP3672584A1 (en) 2020-07-01
US20200323837A1 (en) 2020-10-15
AU2024203839A1 (en) 2024-06-27
US20220288050A1 (en) 2022-09-15
JP2025166032A (ja) 2025-11-05

Similar Documents

Publication Publication Date Title
AU2024203839A1 (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
ES2301142T3 (es) Combinaciones que comprenden inhibidores de dipeptidilpeptidasa-iv y agentes antidiabeticos.
SA96160590B1 (ar) تركيبة صيدلانية
US7115563B2 (en) Composition and its therapeutic use
JPS59130223A (ja) 相乗作用を示す抗ヘルペス組成物
EP1643846A1 (en) Method for treatment of sores and lesions of the skin
Zarubaev et al. Protective activity of ascorbic acid at influenza infection
AU2003204391A1 (en) Composition and its therapeutic use
US20250268967A1 (en) Nutraceutical compounds useful in the treatment of coronavirus disease
HK40026056A (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
WO2019135215A2 (en) Herbal extracts for treatment of herpesvirus infections
US20220249416A1 (en) Synergistic combinations of synthetic lysine analogs, derivatives, mimetics, or prodrugs and pharmaceutical agents for enhanced efficacy
US9757396B2 (en) Method for treating recurring skin and mucous membrane diseases caused by HSV-1 and HSV-2
KR20240038625A (ko) Spil 단백질을 유효성분으로 포함하는 골질환 예방 또는 치료용 약학 조성물
US20160199318A1 (en) Anti-Viral Compound and Composition
Palamara et al. GSH, GSH Derivatives, and Antiviral Activity
HK1067551B (en) Antiviral compositions comprising phenylacetic acid derivatives
HK1067551A1 (en) Antiviral compositions comprising phenylacetic acid derivatives